Kyle Landskroner
- Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertensionBy Marc Iglarz, Kyle Landskroner, Daniel Wanner, Markus Rey, Patrick Hess and Martine ClozelMarc IglarzPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandKyle LandskronerPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandDaniel WannerPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMarkus ReyPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandPatrick HessPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMartine ClozelPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.